Abstract 114P
Background
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma. Systemic Inflammatory Index (SII) has been evaluated as a prognostic biomarker in different solid neoplasms, such as melanoma.
The aim of this work was to evaluate the SII prognostic value in metastatic melanoma patients under first line ICIs.
Methods
Retrospective, single-center study of metastatic melanoma patients who received first- line ICIs between January/2017 and August/2021.
The SII [Platelets x neutrophil/lymphocyte ratio (NLR)] was calculated before ICIs start and was considered high if > 572 (Zhong JH et al. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017 Jun 29;8(43):75381-75388.)
Results
Fifty-one patients enrolled, 32 male, median age at diagnosis 67 years [30-84]. Twenty were stage IV at diagnosis. In patients not stage IV at diagnosis, the median time to metastasis was 11 months [0-279]. Median follow-up time was 7 months [0-54]. The median progression-free survival (PFS) and overall survival (OS) was, respectively, 7 months [1.7-12.2] and 19 months [4.9-33.0]. A total of 24 patients were included in the high SII group. The median PFS and OS were, respectively, 10 months [95%CI, 4.0-15.9, p=0.008] and 29 months [95% CI, 13.8-44.1, p=0.022] in the low SII group and 1 month [95% CI, 0.0-3.7, p=0.008] and 7 months [95% CI, 5.1-8.9, p=0.022] in the high IIS group. Multivariate analysis, showed as independent predictors of survival the NLR [p=0.001, HR 0.520, 95%CI 0.349-0.69] and thrombocytosis [p=0.034, HR 0.160, 95%CI 0.055- 0.265].
Conclusions
This paper shows the prognostic value of SII in metastatic malignant melanoma patients. It may become an important low-cost tool in the management and multidisciplinary approach of these patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.